Abstract
Background and Objectives
In Japan, polypharmacy reduction policy, which reduces the reimbursement of medical cost, was introduced to address unnecessary psychotropic polypharmacy. The rule was applied to the prescriptions of three or more anxiolytics or three or more hypnotics in the policy introduced in 2012. The prescriptions of four or more antidepressants or four or more antipsychotics were added to the rule in the policy revised in 2014. Furthermore, the prescriptions of three or more drugs of anxiolytics, hypnotics, antidepressants, or antipsychotics were subject to the reduction criteria of the policy revision in 2016. Benzodiazepine receptor agonists (BZs) are classified both into anxiolytics and hypnotics, and the reduction rule was not applied to the category of BZs before April 2018. This study aimed to examine the effect of the policy on the prescriptions of four drug categories as well as BZs from the point of view of the number of drugs and doses.
Methods
This was a retrospective observational study using a large-scale Japanese health insurance claims database. Patients who were prescribed at least one psychotropic drug (anxiolytic, hypnotic, antidepressant, or antipsychotic) during the study period (from April 2011 to March 2017) were selected. Segmented regression analysis was used to analyze the proportions of patients with three or more or four or more drugs as well as patients above clinically recommended doses, and the means of the average daily doses by drug category.
Results
A total of 312,167 patients were identified as a study population. The proportions of patients with three or more drugs in anxiolytics, hypnotics, antidepressants, and antipsychotics significantly decreased after the introduction or revisions of the policy, but not BZs. The proportions of patients with three or more drugs in March 2017 were 0.9%, 2.0%, 1.2%, 2.4%, and 8.9% in anxiolytics, hypnotics, antidepressants, antipsychotics, and BZs, respectively. The effect of the policy in reducing the proportions of patients above clinically recommended doses was identified in antipsychotics after the revision in 2016, but not identified in the sum of anxiolytics and hypnotics as well as BZs after the revision in 2014, and antidepressants after the revision in 2016. The proportions of monotherapy were increased from April 2011 to March 2017 only for antidepressants (76.9% → 80.8%) and antipsychotics (79.8% → 82.1%), and not changed or decreased for anxiolytics (85.2% → 85.7%), hypnotics (78.6% → 77.6%), sum of anxiolytics and hypnotics (68.1% → 65.7%), BZs (68.0% → 67.3%), and sum of psychotropic drugs (52.1% → 49.9%).
Conclusions
The polypharmacy reduction policy reduced the proportions of patients with three or more drugs in four drug categories, but not BZs. Only limited effects were seen for reducing the proportions of patients above clinically recommended doses. The policy was revised in April 2018 again. Further investigation is needed to examine the effect of the revision in 2018.
Similar content being viewed by others
References
Linden M, Lecrubier Y, Bellantuono C, Benkert O, Kisely S, Simon G. The prescribing of psychotropic drugs by primary care physicians: an international collaborative study. J Clin Psychopharmacol. 1999;19:132–40.
Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry. 2010;67:26–36.
Nørgaard A, Jensen-Dahm C, Gasse C, Hansen ES, Waldemar G. Psychotropic polypharmacy in patients with dementia: prevalence and predictors. J Alzheimers Dis. 2017;56:707–16.
Hung GC, Yang SY, Chen Y, Lin SK. Psychotropic polypharmacy for the treatment of bipolar disorder in Taiwan. Psychiatr Serv. 2014;65:125–8.
Mishima K. Survey on prescription of psychotropic drugs using claims data (in Japanese). Domestic and international comparative study for psychotropic prescriptions, 2010 study report. Tokyo: Ministry of Health, Labour and Welfare study results database; 2012. p. 15–30.
Arakawa R, Okumura Y, Ikeno T, Kim Y, Ito H. Actual status of prescription patterns of anxiolytics and hypnotics in outpatients using National Database of Health Insurance Claim Information and Specific Medical Checkups (in Japanese). Jpn J Clin Psychiatry. 2015;44:1003–10.
National Association of State Mental Health Program Directors (NASMHPD) Medical Directors Council and State Medicaid Directors. Technical report on psychiatric polypharmacy. 2001. Available from: https://www.nasmhpd.org/sites/default/files/Polypharmacy.pdf. Accessed 11 July 2019.
Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry. 2007;68:1751–62.
Galling B, Roldán A, Hagi K, Rietschel L, Walyzada F, Zheng W, et al. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry. 2017;16:77–89.
Inada K. Problem of polypharmacy (in Japanese). Modern Physician. 2014;34:665–8.
Tiihonen J, Suokas JT, Suvisaari JM, Haukka J, Korhonen P. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry. 2012;69:476–83.
Gören JL, Parks JJ, Ghinassi FA, Milton CG, Oldham JM, Hernandez P, et al. When is antipsychotic polypharmacy supported by research evidence? Implications for QI. Jt Comm J Qual Patient Saf. 2008;34:571–82.
Urichuk L, Prior TI, Dursun S, Baker G. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008;9:410–8.
Westaway K, Sluggett JK, Alderman C, Procter N, Roughead E. Prevalence of multiple antipsychotic use and associated adverse effects in Australians with mental illness. Int J Evid Based Healthc. 2016;14:104–12.
Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry. 1996;153:311–20.
Preskorn SH, Borges-Gonzalez S, Flockhart D. Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: part II. J Psychiatr Pract. 2006;12:312–6.
National Institute for Health and Care Excellence. Depression in adults: recognition and management. Clinical guideline [CG90]. Last updated: 2018. Available from: https://www.nice.org.uk/guidance/cg90. Accessed 11 July 2019.
Herzog DP, Wagner S, Ruckes C, Tadic A, Roll SC, Härter M, et al. Guideline adherence of antidepressant treatment in outpatients with major depressive disorder: a naturalistic study. Eur Arch Psychiatry Clin Neurosci. 2017;267:711–21.
The American Psychiatric Association. Practice guidelines for the psychiatric evaluation of adults. 3rd ed. 2015. Available from: https://doi.org/10.1176/appi.books.9780890426760.pe02. Accessed 31 July 2019.
Ministry of Health, Labour and Welfare. Medical fee revision (in Japanese). Available from: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000106602.html. Accessed 11 July 2019.
Okumura Y, Inada K, Matsumoto T, Shimizu S. Changes in high-dose and combined anxiolytic-hypnotic prescription in outpatient psychiatric practice after regulatory action (in Japanese). Jpn J Clin Psychopharmacol. 2015;18:1173–88.
Medicines Management Programme. Guidance on appropriate prescribing of benzodiazepines and z-drugs (BZRA) in the treatment of anxiety and insomnia. 2018. Available from: https://www.hse.ie/eng/about/who/cspd/ncps/medicines-management/bzra-for-anxiety-insomnia/bzraguidancemmpfeb18.pdf. Accessed 11 July 2019.
Tamburin S, Federico A, Faccini M, Casari R, Morbioli L, Sartore V, et al. Determinants of quality of life in high-dose benzodiazepine misusers. Int J Environ Res Public Health. 2017. https://doi.org/10.3390/ijerph14010038.
Inagaki A, Tomita M. Novel antipsychotics, antipsychotic polypharmacy and high-dose treatment in Japan (in Japanese). Jpn J Clin Psychopharmacol. 2003;6:391–401.
Nakagawa A, Mishima K, Inagami A, et al. International comparison of psychotropic medication prescription patterns (in Japanese). Special Research Summary Report in 2010. 2012. Available from: http://mhlw-grants.niph.go.jp/niph/search/NIDD00.do?resrchNum=201005018A. Accessed 11 July 2019.
Park YC, Yang SY, Chong MY, Kanba S, Sartorius N, Shinfuku N, et al. Differences in high dose antipsychotic prescriptions in patients with schizophrenia in Asian countries/areas: findings from the REAP-AP Study. Psychiatry Investig. 2018;15:1007–8.
Shinfuku N, Tan CH. Pharmacotherapy for schizophrenic inpatients in East Asia: changes and challenges. Int Rev Psychiatry. 2008;20:460–8.
Inagaki A. Validity of high-dose and multiple prescription of antipsychotics (in Japanese). Schizophr Front. 2005;6:58–62.
Nakamura K. Diagnosis procedure combination database would develop nationwide clinical research in Japan. Circ J. 2016;80:2289–90.
Inagaki A, Inada T. Dose equivalence of psychotropic drugs. Part XXIV: dose equivalence of anti-anxiolytics/hypnotics: eszopiclone (in Japanese). Jpn J Clin Psychopharmacol. 2012;15:1403–6.
Inagaki A, Inada T. Dose equivalence of psychotropic drugs. Part XVIII: dose equivalence of psychotropic drugs: 2006-version (in Japanese). Jpn J Clin Psychopharmacol. 2006;9:1443–7.
Inagaki A, Inada T. Dose equivalence of psychotropic drugs. Part XXVII: dose equivalence of novel antidepressants II: venlafaxine (in Japanese). Jpn J Clin Psychopharmacol. 2018;21:547–62.
Inagaki A, Inada T. Dose equivalence of psychotropic drugs. Part XX: dose equivalence of injectable antipsychotics (in Japanese). Jpn J Clin Psychopharmacol. 2007;10:2373–7.
Inagaki A, Inada T. Dose equivalence of psychotropic drugs. Part XXI: dose equivalence of novel antipsychotics: blonanserin (in Japanese). Jpn J Clin Psychopharmacol. 2008;11:887–90.
Inagaki A, Inada T. Dose equivalence of psychotropic drugs. Part XXII: dose equivalence of depot antipsychotics III: risperidone long-acting injection (in Japanese). Jpn J Clin Psychopharmacol. 2010;13:1349–53.
Inagaki A, Inada T. Dose equivalence of psychotropic drugs. Part XXV: dose equivalence of depot antipsychotics IV: aripiprazole once-monthly (in Japanese). Jpn J Clin Psychopharmacol. 2015;18:1475–80.
Inagaki A, Inada T. Dose equivalence of psychotropic drugs. Part XXVI: dose equivalence of novel antipsychotics: asenapine (in Japanese). Jpn J Clin Psychopharmacol. 2017;20:89–97.
Department of Health, Ministry of Health, Labour and Welfare. Entry spec of claims through online or optical disk (version April 2012) (in Japanese). Various information of medical fee. 2012. Available from: http://www.iryohoken.go.jp/shinryohoshu/file/spec/24bt1_1_kiroku.pdf. Accessed 11 July 2019.
Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27:299–309.
Brett J, Daniels B, Karanges EA, Buckley NA, Schneider C, Nassir A, et al. Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study. Br J Clin Pharmacol. 2017;83:2581–8.
Tanaka M, Nagai H, Uchida N, Kawaguchi Y, Fujii S, Nishimura R, et al. The pattern of antidepressant usage in East Asia: international collaborative prescription survey among 5 Asian countries and regions (REAP-AD) (in Japanese). Jpn J Clin Psychopharmacol. 2007;10:131–46.
Inagaki A. Antipsychotic polypharmacy: a comparison between Japan and foreign countries (in Japanese). Jpn J Psychiatr Treat. 2003;18:771–7.
Inagaki A. Current status of antipsychotic polypharmacy in the treatment for schizophrenia (in Japanese). Jpn J Clin Psychopharmacol. 2019;22:347–57.
Tanabe A. A study of reducing the number of antipsychotic drugs in chronic schizophrenia (in Japanese). Keio J Med. 2000;77:231–9.
Sukegawa T, Ito T, Hasegawa M, Mizuno Y, Inagaki A, Sakamoto H, et al. A randomized controlled trial on the dose reduction and simplification for polypharmacy of antipsychotics (in Japanese). Tottori J Clin Res. 2008;1:169–81.
Yamanouchi Y, Sukegawa T, Inagaki A, Inada T, Yoshio T, Yoshimura R, et al. Evaluation of the individual safe correction of antipsychotic agent polypharmacy in Japanese patients with chronic schizophrenia: validation of safe corrections for antipsychotic polypharmacy and the high-dose method. Int J Neuropsychopharmacol. 2015;18:1–8.
Shinfuku N, Hayakawa K, Shih-ku L, Kato T. Problems of Japan’s psychotropic prescription based on the Research on East Asian Psychotropic Prescription Pattern (REAP) (in Japanese). Jpn J Clin Psychopharmacol. 2017;20:983–91.
Lai LL, Bleidt BA, Singh-Franco D, Elusma C, Huh G. Trends in benzodiazepine prescribing under Medicare Part D in USA: outpatient settings 2005–2009. J Pharm Health Serv Res. 2015;6:133–8.
Stubbings J, Lau DT. Medicare Part D research highlights and policy updates, 2013: impact and insights. Clin Ther. 2013;35:402–12.
Hoebert JM, Souverein PC, Mantel-Teeuwisse AK, Leufkens HG, van Dijk L. Reimbursement restriction and moderate decrease in benzodiazepine use in general practice. Ann Fam Med. 2012;10:42–9.
Clay E, Falissard B, Moore N, Toumi M. Contribution of prolonged-release melatonin and anti-benzodiazepine campaigns to the reduction of benzodiazepine and Z-drugs consumption in nine European countries. Eur J Clin Pharmacol. 2013;69:1–10.
Rat C, Penhouet G, Gaultier A, Chaslerie A, Pivette J, Nguyen JM, et al. Did the new French pay-for-performance system modify benzodiazepine prescribing practices? BMC Health Serv Res. 2014;14:301.
Chen H, Nwangwu A, Aparasu R, Essien E, Sun S, Lee K. The impact of Medicare Part D on psychotropic utilization and financial burden for community-based seniors. Psychiatr Serv. 2008;59:1191–7.
Ministry of Education Culture, Sports, Science and Technology, Ministry of Health, Labour and Welfare. Ethical guidelines for epidemiological research. 2002. Available from: http://www.niph.go.jp/wadai/ekigakurinri/guidelines.pdf. Accessed 11 July 2019.
Acknowledgements
MinaCare Co., Ltd. provided the claims data. The authors acknowledge Mamoru Narukawa (Kitasato University) and Masayuki Kaneko (Kitasato University) for their useful advice on this study. The authors also acknowledge John Fowler for the grammar check.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
Pfizer Japan Inc. provided financial support for the use of claims data.
Conflict of interest
Yoko Hirano is an employee of Pfizer Pharmaceuticals K.K. Yoichi Ii is an employee of Pfizer R&D Japan G.K. and holds stock/stock options of Pfizer Inc.
Ethics approval
This study did not require ethical committee review in accordance with current ethical standards for epidemiological studies in Japan [54].
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Hirano, Y., Ii, Y. Changes in Prescription of Psychotropic Drugs After Introduction of Polypharmacy Reduction Policy in Japan Based on a Large-Scale Claims Database. Clin Drug Investig 39, 1077–1092 (2019). https://doi.org/10.1007/s40261-019-00838-w
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40261-019-00838-w